Sopharma AD (SPH.WA)
- Previous Close
13.05 - Open
13.05 - Bid 13.10 x --
- Ask 13.85 x --
- Day's Range
13.05 - 13.05 - 52 Week Range
10.70 - 18.90 - Volume
95 - Avg. Volume
266 - Market Cap (intraday)
2.116B - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
8.53 - EPS (TTM)
1.53 - Earnings Date --
- Forward Dividend & Yield 3.35 (25.64%)
- Ex-Dividend Date Dec 7, 2023
- 1y Target Est
4.20
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of the reproductive system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers public opinion research services. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
www.sopharmagroup.com4,721
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: SPH.WA
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPH.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPH.WA
Valuation Measures
Market Cap
2.10B
Enterprise Value
2.55B
Trailing P/E
8.56
Forward P/E
10.09
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.44
Price/Book (mrq)
1.27
Enterprise Value/Revenue
1.36
Enterprise Value/EBITDA
14.18
Financial Highlights
Profitability and Income Statement
Profit Margin
5.04%
Return on Assets (ttm)
4.19%
Return on Equity (ttm)
13.48%
Revenue (ttm)
1.89B
Net Income Avi to Common (ttm)
95.21M
Diluted EPS (ttm)
1.53
Balance Sheet and Cash Flow
Total Cash (mrq)
128.88M
Total Debt/Equity (mrq)
46.56%
Levered Free Cash Flow (ttm)
125.61M
Research Analysis: SPH.WA
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: SPH.WA
SPH.WA does not have Company Insights